JP2021534752A5 - - Google Patents

Info

Publication number
JP2021534752A5
JP2021534752A5 JP2021509790A JP2021509790A JP2021534752A5 JP 2021534752 A5 JP2021534752 A5 JP 2021534752A5 JP 2021509790 A JP2021509790 A JP 2021509790A JP 2021509790 A JP2021509790 A JP 2021509790A JP 2021534752 A5 JP2021534752 A5 JP 2021534752A5
Authority
JP
Japan
Prior art keywords
cells
amino acid
seq
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047550 external-priority patent/WO2020041501A1/en
Publication of JP2021534752A publication Critical patent/JP2021534752A/ja
Publication of JP2021534752A5 publication Critical patent/JP2021534752A5/ja
Pending legal-status Critical Current

Links

JP2021509790A 2018-08-22 2019-08-21 Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法 Pending JP2021534752A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721439P 2018-08-22 2018-08-22
US62/721,439 2018-08-22
PCT/US2019/047550 WO2020041501A1 (en) 2018-08-22 2019-08-21 Immunotherapy targeting kras or her2 antigens

Publications (2)

Publication Number Publication Date
JP2021534752A JP2021534752A (ja) 2021-12-16
JP2021534752A5 true JP2021534752A5 (OSRAM) 2022-08-31

Family

ID=68000056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509790A Pending JP2021534752A (ja) 2018-08-22 2019-08-21 Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法

Country Status (11)

Country Link
US (1) US20210340201A1 (OSRAM)
EP (1) EP3841113A1 (OSRAM)
JP (1) JP2021534752A (OSRAM)
KR (1) KR20210049119A (OSRAM)
CN (1) CN112912387A (OSRAM)
AU (1) AU2019324162A1 (OSRAM)
BR (1) BR112021003031A8 (OSRAM)
CA (1) CA3109496A1 (OSRAM)
IL (1) IL280804A (OSRAM)
MX (1) MX2021001938A (OSRAM)
WO (1) WO2020041501A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
US20240100162A1 (en) * 2020-12-22 2024-03-28 Amgen Inc. Mage-b2-specific t-cell receptors
CN113755495B (zh) * 2021-09-22 2022-09-06 陈天睿 基因编辑技术在治疗癌症中的应用
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
CN121487961A (zh) * 2023-05-06 2026-02-06 百奥赛图(北京)医药科技股份有限公司 抗kras/hla抗体及其用途
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
CN119409800B (zh) * 2025-01-06 2025-04-01 北京可瑞生物科技有限公司 亲和力提升的tcr或其片段以及用途
CN121471339B (zh) * 2026-01-12 2026-03-27 北京立康生命科技有限公司 特异性结合her2来源肽段的t细胞受体及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
CN101284873A (zh) * 1999-06-30 2008-10-15 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
NZ609460A (en) * 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
EP2896697B1 (en) 2012-12-12 2015-09-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン， インコーポレイテッド 抗ヒトｂ７−ｈ４抗体およびその使用
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
PT3079715T (pt) * 2013-12-09 2018-08-02 Targovax Asa Uma mistura de péptidos
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
SG11201706583PA (en) 2015-02-19 2017-09-28 Compugen Ltd Anti-pvrig antibodies and methods of use
MX2017015927A (es) * 2015-06-16 2018-04-18 Targovax Asa Fragmentos mutantes de proteina ras.
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CR20180519A (es) * 2016-03-31 2019-03-05 Neon Therapeutics Inc Neoantígenos y métodos de su uso
US11723962B2 (en) 2016-05-04 2023-08-15 Fred Hutchinson Cancer Center Cell-based neoantigen vaccines and uses thereof
EP3452514A1 (en) * 2016-05-06 2019-03-13 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1

Similar Documents

Publication Publication Date Title
JP7037577B2 (ja) 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
US20210340201A1 (en) Immunotherapy targeting kras or her2 antigens
US11738047B2 (en) Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
US12398191B2 (en) BRAF-specific TCRs and uses thereof
JP2025517945A (ja) ネオ抗原に特異的な結合タンパク質及び操作された細胞、ならびにその使用
JP2020535796A (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
JP7611844B2 (ja) 高アビディティｗｔ１ｔ細胞受容体とその使用
JP2020533289A5 (OSRAM)
JP2020533289A (ja) 養子細胞治療を改善するための方法
US12595290B2 (en) T cell receptors specific for mesothelin and their use in immunotherapy
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
CN114555790A (zh) Wt-1特异性t细胞免疫疗法
US20220401537A1 (en) Chimeric receptor proteins and uses thereof
HK40060048B (zh) 间皮素特异性t细胞受体及其在免疫治疗中的应用
EA048447B1 (ru) Высокоавидные т-клеточные рецепторы к wt1 и их применения